Early Multicentre Real-World Outcomes of AnyraTM, a Novel Aflibercept Biosimilar, in Treatment-Naïve Retinal Diseases
Ophthalmology and Therapy · 18.11.2026
DOI: 10.1007/s40123-026-01538-3 ↗Kurz gefasst
Fachartikel in der Zeitschrift Ophthalmology and Therapy, online erschienen am 18.11.2026. Verfasst von Somnath Chakraborty und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Vitreoretinal Services, Retina Institute of Bengal, Siliguri, West Bengal, India. somnathboom@gmail.com. Die Arbeit nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
We aimed to evaluate the early functional, anatomical and safety outcomes of Anyra TM (Zydus Lifesciences Ltd., Ahmedabad, India), a novel aflibercept biosimilar (Afl-Bs), in treatment-naïve eyes with neovascular age-related macular degeneration (nAMD), diabetic macular oedema (DME), retinal vein occlusion (RVO) or myopic macular neovascularization (MNV). This multicentre retrospective observational study included 162 consecutive treatment-naïve eyes from 162 patients treated with a single intravitreal injection of Afl-Bs at five tertiary retina centres in India between April 2026 and May 2026. The cohort comprised 82 eyes with nAMD, 40 eyes with DME, 36 eyes with RVO and 4 eyes with myopic MNV. Best-corrected visual acuity (BCVA), converted to logarithm of the minimum angle of resolution (logMAR), central macular thickness (CMT), intraretinal fluid (IRF), subretinal fluid (SRF) and complete retinal drying were evaluated at baseline and 1 month. Paired t -tests and McNemar tests were used, as appropriate. Mean BCVA improved from 0.77 ± 0.40 logMAR at baseline to 0.55 ± 0.39 logMAR at 1 month (mean difference, −0.22 ± 0.26 logMAR; P < 0.001). Mean CMT decreased from 480.67 ± 207.8 µm to 309.13 ± 163.4 µm (mean difference, −71.54 ± 170.8 µm; P < 0.001). IRF was present in 120 eyes (74.1%) at baseline and 40 eyes (24.7%) at 1 month ( P < 0.001); SRF decreased from 82 eyes (50.6%) to 33 eyes (20.4%) ( P < 0.001). Complete retinal drying was observed in 96 eyes (59.3%) at 1 month. Significant improvements in BCVA and CMT were observed across nAMD, DME and RVO subgroups. No ocular or systemic adverse events were observed during follow-up. Early multicentre real-world experience suggests that Afl-Bs provides favourable short-term functional and anatomical outcomes across common retinal diseases, with no unexpected adverse events documented during the study period. Larger prospective comparative studies with longer follow-up are warranted to further evaluate its clinical effectiveness and safety.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Vitreoretinal Services, Retina Institute of Bengal, Siliguri, West Bengal, India. somnathboom@gmail.com.
- Department of Retina Services, Shantilal Shanghvi Eye Institute, Mumbai, Maharashtra, India.
- Department of Vitreoretinal Services, MS Sudhalkar Research Foundation, Baroda, Gujrat, India.
- Department of Vitreoretinal Services, Kar Vision Eye Hospital, Bhubaneshwar, Odisha, India.
- Department of Vitreoretinal Services, Drishtideep Eye Institute, Dankuni, West Bengal, India.
- Department of Vitreoretinal Services, Sarakshi Netralaya, Nagpur, Maharashtra, India.
Zitieren
APA
Chakraborty, S., Sheth, J. U., Sudhalkar, A., Kanungo, S., Sinha, S., & Narnaware, S. (2026). Early Multicentre Real-World Outcomes of AnyraTM, a Novel Aflibercept Biosimilar, in Treatment-Naïve Retinal Diseases. Ophthalmology and Therapy. https://doi.org/10.1007/s40123-026-01538-3
Vancouver
Chakraborty S, Sheth JU, Sudhalkar A, Kanungo S, Sinha S, Narnaware S. Early Multicentre Real-World Outcomes of AnyraTM, a Novel Aflibercept Biosimilar, in Treatment-Naïve Retinal Diseases. Ophthalmology and Therapy. 2026. doi:10.1007/s40123-026-01538-3
BibTeX
@article{Chakraborty2026,
author = {Chakraborty, Somnath and Sheth, Jay U and Sudhalkar, Aditya and Kanungo, Sanghamitra and Sinha, Subijay and Narnaware, Shilpi},
title = {Early Multicentre Real-World Outcomes of AnyraTM, a Novel Aflibercept Biosimilar, in Treatment-Naïve Retinal Diseases},
journal = {Ophthalmology and Therapy},
year = {2026},
doi = {10.1007/s40123-026-01538-3}
}
EUVIMED